The effects of pentoxifylline administration on NFΚB P50 transcription factor expression
oleh: Jamal Shamsara, Javad Behravan, Homa Falsoleiman, Amir Houshang Mohammadpour, Mohammad Ramezani
| Format: | Article |
|---|---|
| Diterbitkan: | Vesnu Publications 2011-12-01 |
Deskripsi
<p class="abstract"><strong>BACKGROUND:</strong> Pentoxifylline has anti-inflammatory properties and could suppress some inflammatory processes including tumor necrosis factor-alpha (TNF-α) production. We assessed the effects of a two-month administration of pentoxifylline on nuclear factor-kappa B (NFκB) pathways in patients with coronary artery disease (CAD) in which inflammatory pathways, especially NFκB transcription factors, have a critical role.</p> <p class="abstract"><strong> </strong><strong>METHODS:</strong> A double-blind randomized placebo-controlled study design was used. Forty CAD patients were randomized to either 2 months of pentoxifylline treatment<sup> </sup>(1200 mg/day) (n = 20) or placebo treatment (n = 20). Blood samples were obtained just before and after two months of treatment. P50 protein concentration in peripheral blood mononuclear cells (PBMCs) was measured by Enzyme Linked ImmunoSorbent Assay (ELISA) method.</p> <p class="abstract"><strong> RESULTS: </strong>P50 concentration did not significantly change during two months of pentoxifylline administration.</p> <p class="abstract"><strong> </strong><strong>CONCLUSION:</strong> Longer pentoxifylline administration is needed to see its favorable effects on NFκB family elements.</p> <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td width="35" height="12"><br /></td></tr> <tr><td><br /></td> <td> </td></tr></tbody></table> <strong>Keywords:</strong> Coronary Artery Diseases, Inflammation, NFκB, Pentoxifylline. <p class="abstract"> </p><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td width="35" height="12"><br /></td></tr><tr><td></td><td></td></tr></tbody></table>